A randomized, double-blind, placebo controlled phase II study of AZD2171 [cediranib] plus capecitabine versus capecitabine alone as 1st line therapy in patients with metastatic colorectal cancer
Phase of Trial: Phase II
Latest Information Update: 07 Jul 2006
At a glance
- Drugs Cediranib (Primary) ; Capecitabine
- Indications Colorectal cancer
- Focus Therapeutic Use
- 07 Jul 2006 New trial record.